HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Shanghai HeartCare Medical Technology / Equity Capital Markets

Shanghai HeartCare Medical Technology (6609 HK)

<p>On January 27<sup>th</sup>, 2021, <a href="https://www.smartkarma.com/entities/shanghai-heartcare-medical-technology-corporation-limited" target="_blank" data-smartkarma-citation="entities:32192:1" rel="noopener">Shanghai HeartCare Medical Technology (HMT HK)</a> filed its prospectus on the Hong Kong Stock Exchange. HeartCare was founded in 2016, focusing on the development and industrialization of neuro-interventional technology innovations for stroke prevention and treatment. Over the past four years or so, the Company has raised five rounds of funding, with three rounds of equity funding last year, and now it officially launches its IPO plan. HeartCare has not been established for a long time, why could it frequently obtain the capital favor?</p>

On January 27th, 2021, Shanghai HeartCare Medical Technology (HMT HK) filed its prospectus on the Hong Kong Stock Exchange. HeartCare was founded in 2016, focusing on the development and industrialization of neuro-interventional technology innovations for stroke prevention and treatment. Over the past four years or so, the Company has raised five rounds of funding, with three rounds of equity funding last year, and now it officially launches its IPO plan. HeartCare has not been established for a long time, why could it frequently obtain the capital favor?

Pre-IPO Shanghai HeartCare Medical Technology - Promising Market but Fierce Competition

China

Zylox-Tonbridge Medical Technology is a medical technology company dedicated to the innovative research, development, manufacturing, and commercialization of neurovascular and peripheral vascular interventional devices. Its product portfolio includes devices such as the Thrombite Clot Retriever Device, Ultrafree Drug Coated PTA Balloon Catheter, and Zenflex Peripheral Stent System. The company was founded in 2012 and is headquartered in Hangzhou, China.

Zylox-Tonbridge Medical Technology (2190 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO Shanghai HeartCare Medical Technology - Promising Market but Fierce Competition

This article analyzed HeartCare Medical in terms of industry characteristics in China, market potential, competitive landscape, financial position,...

Xinyao (Criss) Wang